Cell Source, Inc. Files 10-Q for Q2 2024
Ticker: CLCS · Form: 10-Q · Filed: Aug 19, 2024 · CIK: 1569340
| Field | Detail |
|---|---|
| Company | Cell Source, Inc. (CLCS) |
| Form Type | 10-Q |
| Filed Date | Aug 19, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, company-information, pharmaceuticals
TL;DR
**Cell Source, Inc. 10-Q filed. Check financials for Q2 2024.**
AI Summary
Cell Source, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as TICKET TO SEE, INC., is incorporated in Nevada and operates in the Pharmaceutical Preparations sector. Its business and mailing address is 57 West 57th Street, Suite 400, New York, NY 10019, with a business phone number of 646-612-7554.
Why It Matters
This filing provides investors with an update on Cell Source, Inc.'s financial performance and operational status for the second quarter of 2024.
Risk Assessment
Risk Level: low — The provided text is a header and basic company information from a 10-Q filing, lacking detailed financial performance or operational risk disclosures.
Key Players & Entities
- Cell Source, Inc. (company) — Filer
- TICKET TO SEE, INC. (company) — Former company name
- 20240630 (date) — Reporting period end date
- 20240819 (date) — Filing date
- 57 WEST 57TH STREET SUITE 400 NEW YORK NY 10019 (address) — Business and mailing address
- 646-612-7554 (phone_number) — Business phone number
FAQ
What is the primary business of Cell Source, Inc.?
Cell Source, Inc. operates in the Pharmaceutical Preparations sector, SIC code 2834.
When is the reporting period for this 10-Q filing?
The conforming period of report is June 30, 2024.
What was Cell Source, Inc. formerly known as?
The company was formerly known as TICKET TO SEE, INC.
In which state is Cell Source, Inc. incorporated?
Cell Source, Inc. is incorporated in Nevada (NV).
What is the business address of Cell Source, Inc.?
The business address is 57 WEST 57TH STREET, SUITE 400, NEW YORK, NY 10019.
Filing Stats: 4,599 words · 18 min read · ~15 pages · Grade level 19.5 · Accepted 2024-08-19 15:12:43
Filing Documents
- form10-q.htm (10-Q) — 1399KB
- ex10-70.htm (EX-10.70) — 29KB
- ex10-71.htm (EX-10.71) — 27KB
- ex31.htm (EX-31) — 13KB
- ex32.htm (EX-32) — 7KB
- ex10-71_001.jpg (GRAPHIC) — 32KB
- ex10-71_002.jpg (GRAPHIC) — 41KB
- ex10-71_003.jpg (GRAPHIC) — 190KB
- ex10-71_004.jpg (GRAPHIC) — 106KB
- ex10-71_005.jpg (GRAPHIC) — 254KB
- 0001493152-24-033055.txt ( ) — 6241KB
- clcs-20240630.xsd (EX-101.SCH) — 29KB
- clcs-20240630_cal.xml (EX-101.CAL) — 34KB
- clcs-20240630_def.xml (EX-101.DEF) — 212KB
- clcs-20240630_lab.xml (EX-101.LAB) — 266KB
- clcs-20240630_pre.xml (EX-101.PRE) — 234KB
- form10-q_htm.xml (XML) — 863KB
- FINANCIAL INFORMATION
PART I - FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements. 3 Condensed Consolidated Balance Sheets as of June 30, 2024 (Unaudited) and December 31, 2023 3 Unaudited Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2024 and 2023 4 Unaudited Condensed Consolidated Statements of Changes in Stockholders' Deficiency for the Three and Six Months Ended June 30, 2024 and 2023 5 Unaudited Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023 6 Notes to Unaudited Condensed Consolidated Financial Statements 7
Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. 13
Quantitative and Qualitative Disclosures About Market Risk
Item 3. Quantitative and Qualitative Disclosures About Market Risk. 17
Controls and Procedures
Item 4. Controls and Procedures. 17
- OTHER INFORMATION
PART II - OTHER INFORMATION
Legal Proceedings
Item 1. Legal Proceedings. 18
Risk Factors
Item 1A. Risk Factors. 18
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 18
Defaults Upon Senior Securities
Item 3. Defaults Upon Senior Securities. 18
Mine Safety Disclosures
Item 4. Mine Safety Disclosures. 18
Other Information
Item 5. Other Information. 18
Exhibits
Item 6. Exhibits. 18
SIGNATURES
SIGNATURES 19 2 PART I – FINANCIAL INFORMATION Item 1. Financial Statements. CELL SOURCE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, December 31, 2024 2023 (Unaudited) Assets Current Assets: Cash $ 90,549 $ 22,203 Prepaid expenses 321,500 160,750 Other current assets 17,718 12,218 Total Assets $ 429,767 $ 195,171 Liabilities and Stockholders' Deficiency Current Liabilities: Accounts payable $ 1,751,867 $ 1,467,052 Accrued expenses 1,390,363 1,225,195 Accrued expenses - related party 173,500 144,500 Accrued expenses 173,500 144,500 Accrued interest 976,840 939,549 Accrued interest - related parties 1,806,964 1,480,117 Accrued interest 1,806,964 1,480,117 Accrued compensation 1,016,127 960,554 Notes payable, net of debt discount of $ 115,614 and $ 776 as of June 30, 2024 and December 31, 2023, respectively 889,229 710,317 Notes payable - related parties, net of debt discount of $ 115,614 and $ 0 as of June 30, 2024 and December 31, 2023, respectively 328,136 150,000 Notes payable 328,136 150,000 Convertible notes payable, net of debt discount of $ 10,551 and $ 16,179 as of June 30, 2024 and December 31, 2023, respectively 984,449 1,078,821 Convertible notes payable - related parties 7,461,708 7,315,036 Convertible notes payable 7,461,708 7,315,036 Derivative liabilities 235,093 33,000 Derivative liabilities - related party 142,365 - Derivative liabilities 142,365 - Financing liability 343,533 42,033 Advances payable 135,000 135,000 Advances payable - related party 100,000 100,000 Advances payable 100,000 100,000 Accrued dividend payable 14,094 25,540 Total Liabilities 17,749,268 15,806,714 Commitments and contingencies (Note 8) - - Stockholders' Deficiency: Convertible Preferred Stock, $ 0.001 par value, 10,000,000 shares authorized; Series A Convertible Preferred Stock, 1,350,000 shares designated, 1,342,195 shares